SBIO holdings

All 89 positions of ALPS Medical Breakthroughs ETF.

Download CSV

Positions

Top 10 weight

34.8%

Effective holdings

46.9

1 / sum of squared weights

In stocks

100.0%

In bonds

0.0%

Outside the US

19.8%

Asset mix

Equity100.0%

Sectors

100% of stocks classified

Health Care100.0%

Countries

United States80.2%
Netherlands4.7%
Cayman Islands4.7%
Ireland4.5%
Canada2.9%
Belgium1.2%
United Kingdom1.1%
Switzerland0.8%

Holdings

#	Holding	Type	Weight	Value	Shares / par	Country
1	ALKSAlkermes Inc. plc	Equity	4.48%	$7.2M	171,723	IE
2	KYMRKymera Therapeutics, Inc. Common Stock	Equity	4.23%	$6.9M	84,154	US
3	CELCCelcuity Inc. Common Stock	Equity	3.92%	$6.3M	47,693	US
4	MIRMMirum Pharmaceuticals, Inc. Common Stock	Equity	3.90%	$6.3M	62,199	US
5	SYRESpyre Therapeutics, Inc. Common Stock	Equity	3.68%	$6.0M	80,958	US
6	CGONCG Oncology, Inc. Common stock	Equity	3.35%	$5.4M	87,032	US
7	APGEApogee Therapeutics, Inc. Common Stock	Equity	2.93%	$4.7M	57,722	US
8	XENEXenon Pharmaceuticals Inc	Equity	2.90%	$4.7M	85,746	CA
9	TVTXTravere Therapeutics, Inc. Common Stock	Equity	2.77%	$4.5M	95,051	US
10	DNTHDianthus Therapeutics, Inc. Common Stock	Equity	2.64%	$4.3M	45,839	US
11	NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares	Equity	2.47%	$4.0M	118,514	NL
12	VKTXViking Therapeutics, Inc	Equity	2.41%	$3.9M	119,108	US
13	CRNXCrinetics Pharmaceuticals, Inc.	Equity	2.37%	$3.8M	107,892	US
14	ACADAcadia Pharmaceuticals Inc.	Equity	2.35%	$3.8M	175,740	US
15	EWTXEdgewise Therapeutics, Inc. Common Stock	Equity	2.33%	$3.8M	110,576	US
16	DNLIDenali Therapeutics Inc. Common Stock	Equity	2.13%	$3.4M	163,467	US
17	ORKAOruka Therapeutics, Inc. Common Stock	Equity	1.81%	$2.9M	49,896	US
18	GPCRStructure Therapeutics Inc. American Depositary Shares	Equity	1.78%	$2.9M	73,020	KY
19	IRONDisc Medicine, Inc. Common Stock	Equity	1.69%	$2.7M	39,334	US
20	IDYAIDEAYA Biosciences, Inc. Common Stock	Equity	1.65%	$2.7M	90,520	US
21	VERAVera Therapeutics, Inc. Class A Common Stock	Equity	1.61%	$2.6M	73,552	US
22	TARSTarsus Pharmaceuticals, Inc. Common Stock	Equity	1.61%	$2.6M	43,870	US
23	RLAYRelay Therapeutics, Inc. Common Stock	Equity	1.60%	$2.6M	184,224	US
24	MLYSMineralys Therapeutics, Inc. Common Stock	Equity	1.59%	$2.6M	81,578	US
25	CLDXCelldex Therapeutics, Inc	Equity	1.33%	$2.2M	68,615	US
26	ZLABZai Lab Limited American Depositary Shares	Equity	1.26%	$2.0M	115,031	KY
27	PHVSPharvaris N.V. Ordinary Shares	Equity	1.23%	$2.0M	66,026	NL
28	SIONSionna Therapeutics, Inc. Common Stock	Equity	1.23%	$2.0M	46,379	US
29	RAPPRapport Therapeutics, Inc. Common Stock	Equity	1.20%	$1.9M	49,264	US
30	SRPTSarepta Therapeutics,, Inc. Common Stock	Equity	1.20%	$1.9M	108,222	US
31	LKFTLakefront Biotherapeutics American Depositary Shares	Equity	1.19%	$1.9M	67,945	BE
32	TYRATyra Biosciences, Inc. Common Stock	Equity	1.15%	$1.9M	55,509	US
33	NVAXNovavax Inc	Equity	1.14%	$1.8M	167,949	US
34	STOKStoke Therapeutics, Inc. Common Stock	Equity	1.12%	$1.8M	58,873	US
35	AGIOAgios Pharmaceuticals, Inc.	Equity	1.10%	$1.8M	60,392	US
36	VCELVericel Corporation	Equity	1.08%	$1.7M	52,309	US
37	NUVBNuvation Bio Inc.	Equity	1.06%	$1.7M	357,260	US
38	PVLAPalvella Therapeutics, Inc. Common Stock	Equity	1.03%	$1.7M	14,096	US
39	TSHATaysha Gene Therapies, Inc. Common Stock	Equity	1.02%	$1.7M	282,348	US
40	AMLXAmylyx Pharmaceuticals, Inc. Common Stock	Equity	1.01%	$1.6M	113,933	US
41	IMTXImmatics N.V. Ordinary Shares	Equity	0.98%	$1.6M	138,190	NL
42	IMCRImmunocore Holdings plc American Depositary Shares	Equity	0.93%	$1.5M	52,254	GB
43	MBXMBX Biosciences, Inc. Common Stock	Equity	0.90%	$1.5M	46,286	US
44	BCAXBicara Therapeutics Inc. Common Stock	Equity	0.88%	$1.4M	65,313	US
45	MLTXMoonLake Immunotherapeutics Class A Ordinary Shares	Equity	0.88%	$1.4M	73,934	KY
46	KALVKalVista Pharmaceuticals, Inc. Common Stock	Equity	0.87%	$1.4M	52,105	US
47	AVBPArriVent BioPharma, Inc. Common Stock	Equity	0.85%	$1.4M	45,563	US
48	OCSOculis Holding AG Ordinary shares	Equity	0.84%	$1.4M	58,929	CH
49	MAZEMaze Therapeutics, Inc. Common Stock	Equity	0.81%	$1.3M	49,602	US
50	MNKDMannkind Corporation	Equity	0.74%	$1.2M	317,578	US
51	CRVSCorvus Pharmaceuticals, Inc.	Equity	0.66%	$1.1M	86,347	US
52	OLMAOlema Pharmaceuticals, Inc. Common Stock	Equity	0.66%	$1.1M	81,077	US
53	ZBIOZenas BioPharma, Inc. Common Stock	Equity	0.63%	$1.0M	55,332	US
54	KURAKura Oncology, Inc.	Equity	0.57%	$929K	91,050	US
55	SPRYARS Pharmaceuticals, Inc. Common Stock	Equity	0.57%	$928K	102,352	US
56	XNCRXencor, Inc.	Equity	0.56%	$898K	75,597	US
57	TBPHTheravance Biopharma, Inc.	Equity	0.52%	$839K	52,230	KY
58	GERNGeron Corp	Equity	0.51%	$825K	660,249	US
59	DSGNDesign Therapeutics, Inc. Common Stock	Equity	0.41%	$666K	63,568	US
60	ANROAlto Neuroscience Inc.	Equity	0.40%	$643K	32,025	US
61	CADLCandel Therapeutics, Inc. Common Stock	Equity	0.39%	$627K	75,500	US
62	TECXTectonic Therapeutic, Inc. Common Stock	Equity	0.37%	$603K	19,353	US
63	FLGTFulgent Genetics, Inc. Common Stock	Equity	0.36%	$584K	32,191	US
64	RIGLRigel Pharmaceuticals Inc. (New)	Equity	0.36%	$581K	19,042	US
65	ACRSAclaris Therapeutics, Inc.	Equity	0.35%	$566K	124,304	US
66	UPBUpstream Bio, Inc. Common Stock	Equity	0.29%	$466K	55,699	US
67	NGNENeurogene, Inc. Common Stock	Equity	0.28%	$453K	15,968	US
68	CMPXCompass Therapeutics, Inc. Common Stock	Equity	0.27%	$442K	185,633	US
69	ALTAltimmune, Inc. Common Stock	Equity	0.25%	$409K	134,076	US
70	VNDAVanda Pharmaceuticals Inc.	Equity	0.24%	$393K	60,925	US
71	DCTHDelcath Systems Inc	Equity	0.24%	$386K	35,814	US
72	AVIRAtea Pharmaceuticals, Inc. Common Stock	Equity	0.24%	$384K	82,125	US
73	ZURAZura Bio Limited Class A Ordinary Shares	Equity	0.24%	$382K	88,879	KY
74	RGNXREGENXBIO Inc.	Equity	0.23%	$373K	53,200	US
75	RZLTRezolute, Inc. Common Stock (NV)	Equity	0.20%	$326K	98,643	US
76	AVXLAnavex Life Sciences	Equity	0.18%	$289K	95,522	US
77	AKBAAkebia Therapeutics, Inc.	Equity	0.17%	$282K	276,121	US
78	TARAProtara Therapeutics, Inc. Common Stock	Equity	0.16%	$259K	55,748	US
79	FBRXForte Biosciences, Inc. Common Stock	Equity	0.15%	$246K	12,912	US
80	BCYCBicycle Therapeutics plc American Depositary Shares	Equity	0.15%	$241K	51,450	GB
81	ARCTArcturus Therapeutics Holdings Inc. Common Stock	Equity	0.14%	$232K	29,289	US
82	AARDAardvark Therapeutics, Inc. Common Stock	Equity	0.06%	$92K	22,439	US
83	State Street Institutional Treasury Plus Money Market Fund	Cash	0.00%	$7K	6,739	US
84	Astrazeneca Plc	Derivative	0.00%	$0	36,586	US
85	Chinook Therapeutics Inc	Derivative	0.00%	$0	20,700	US
86	Omniab Inc	Derivative	0.00%	$0	3,653	US
87	Novo Nordisk A/s	Derivative	0.00%	$0	1,233	DK
88	Omniab Inc	Derivative	0.00%	$0	3,653	US
89	N/A	Cash	0.00%	$0	—	US

Find which other funds hold a stock by opening it and choosing "ETFs holding".

Position changes between reports

Action	Holding	Weight before	Weight after	Shares vs flows	Between reports
Exit	FOLDAmicus Therapeutics Inc	2.86%	—	—	Feb 28, 2026 → May 31, 2026 SEC
Exit	APLSApellis Pharmaceuticals Inc	1.71%	—	—	Feb 28, 2026 → May 31, 2026 SEC
Increase	MIRMMirum Pharmaceuticals Inc	3.06%	3.90%	+16.1%	Feb 28, 2026 → May 31, 2026 SEC
Exit	DAWNDay One Biopharmaceuticals Inc	0.70%	—	—	Feb 28, 2026 → May 31, 2026 SEC
Increase	GPCRStructure Therapeutics Inc	2.47%	1.78%	+15.5%	Feb 28, 2026 → May 31, 2026 SEC
Increase	BCAXBicara Therapeutics Inc	0.59%	0.88%	+14.4%	Feb 28, 2026 → May 31, 2026 SEC
Increase	CRVSCorvus Pharmaceuticals Inc	0.88%	0.66%	+10.9%	Feb 28, 2026 → May 31, 2026 SEC
Increase	CADLCandel Therapeutics Inc	0.19%	0.39%	+32.0%	Feb 28, 2026 → May 31, 2026 SEC
Increase	ACRSAclaris Therapeutics Inc	0.20%	0.35%	+10.1%	Feb 28, 2026 → May 31, 2026 SEC
Increase	VERAVera Therapeutics Inc	1.68%	1.61%	+10.4%	Feb 28, 2026 → May 31, 2026 SEC
Increase	ZURAZura Bio Ltd	0.28%	0.24%	+31.2%	Feb 28, 2026 → May 31, 2026 SEC
Increase	ALTAltimmune Inc	0.29%	0.25%	+23.3%	Feb 28, 2026 → May 31, 2026 SEC
Increase	PVLAPalvella Therapeutics Inc	1.03%	1.03%	+14.2%	Feb 28, 2026 → May 31, 2026 SEC

Share-count changes are measured after removing what creations and redemptions explain.

Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.